The relationship between the cold chain system and vaccine potency in Taiwan: (I) Live measles vaccine and MMR vaccine

Journal of Food and Drug Analysis

Volumn 7, Issue 3, 1999, Pages 233-242

  Wang, Der Yuan ^a   Yang, Ruoh Ing ^a   Yang, Yi Chen ^a   Yeh, Sheng Yen ^a   Chen, Tso Ling ^a   Cheng, Hwei Fang ^a   Hsieh, Juen Tian ^a   Lin, Chia Po ^a  

^a DEPARTMENT OF HEALTH   (Taiwan)

Author keywords

Cold chain; MMR vaccine; MV; Potency test; Remaining term of validity

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE;

ARTICLE; DARKNESS; DRUG POTENCY; DRUG STABILITY; DRUG STORAGE; PH; TEMPERATURE; VIRUS ATTENUATION;

EID: 0032727391     PISSN: 10219498     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Henderson, D. A. 1980. Smallpox eradication. Public Health Rep. 95: 422-426.
2. Tydeman, M. S. and Kirkwood, T. B. L. 1984. Design and analysis of accelerated degradation tests for the stability of biological standards. I. Properties of maximum likelihood estimators. J. Biol. Stand. 12: 195-206.
3. Rao, Y. U., William, J. and Kalyanaraman, V. R. 1985. A study of the stability of the pertussis component of diphtheria-tetanus-pertussis (DTP) vaccines. J. Biol. Stand. 13: 267-270.
4. Expanded programme on immunization: Heat stability of vaccines. 1988. Wkly Epidemiol Rec. 55: 252-254.
5. Peetermans, J. 1996. Factors affecting the stability of viral vaccine. Dev. Biol. Stand. 87: 97-101.
6. Mcaleer, W. J., Markus, H. Z., McLean, A. A., Buynak, E. B. and Hilleman, M. R. 1980. Stability on storage at various temperatures of live measles, mumps, and rubella virus vaccines in new stabilizer. J. Biol. Stand. 8: 281-287.
7. Haworth, E. A., Booy, R., Stirzaker, L., Wilkers, S. and Battersby, A. 1993. Is the cold chain for vaccines maintained in general practice? BMJ 307: 242-244.
8. Zaffran, M. 1996. Vaccine transport and storage: Environmental challenges. Dev. Biol. Stand. 87: 9-17.
9. Cowdery, S., Frey, M., Orlowski, S. and Gray, A. 1976. Stability characteristics of freeze-dried human live virus vaccines. Dev. Biol. Stand. 36: 297-303.
10. Aggarwal, A. and Singh, A. J. 1995. Evaluation of cold chain system in rural areas of Haryana. Indian Pediatr. 32: 31-34.
11. Guthridge, S. L. and Miller, N. C. 1996. Cold chain in a hot climate. Australian & New Zealand J. Public Health 20: 657-660.
12. Watson, J. C., Hadler, S. C., Dykewicz, C. A., Reef, S. and Phillips, L. 1998. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, mumps, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 47 (No. RR-8): 1-56.
13. Just, M., Berger, R., Gluck, R. and Wegmann, A. 1986. Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Dev. Biol. Stand. 65: 25-27.
14. Pabst, H. F., Spady, D. W., Carson, M. M., Stelfox, H. T., Beeler, J. A. and Krezolek, M. P. 1997. Kinetics of immunologic responses after primary MMR vaccination. Vaccine 15: 10-14.
15. Rathnam, S., West, R., Gadag, V. and Burris, J. 1996. Measles immunization strategy: Measles antibody response following MMR II vaccination of children at one year of age. Can. J. Public Health 87: 97-100.
16. Miller, E., Hill, A., Morgan-Capner, P., Forsey, T. and Rush, M. 1995. Antibodies to measles, mumps, and rubella in UK children 4 years after vaccination with different MMR vaccines. Vaccine 13: 799-802.
17. Ozaki, K., Kuno-Sakai, H. and Kimura, M. 1987. Evaluation of mumps antibodies after measles-mumps-rubella (MMR) vaccines. Tokai J. Exp. Clin. Med. 12: 305-311.
18. Woodyard, E., Woodyard, L. and Alto, W. A. 1995. Vaccine storage in the physician's office: A community study. J. Am. Board Family Practice 8: 91-94.
19. World Health Organization. 1995. Manual of laboratory methods for potency testing of vaccines used in the WHO expanded programme on immunization. pp. 100-103.
20. Reed, L. J. and Muench, H. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hygiene 27: 493-497.
21. de Rizzo, E., Tenorio, E. C., Mendes, I. F., Fang, F. L., Pral, M. M., Takata, C. S., Miyak, C., Gallina, N. M., Tuchiy, H. N. and Akimura, O. K. 1989. Sorbitol-gelatin and glutamic acid-lactose solutions for stabilization of reference preparations of measles virus. Bull. Pan. Am. Health Organ. 23: 299-305.
22. Birkhed, D., Edwardsson, S., Kalfas, S. and Svensater, G. 1984. Cariogenicity of sorbitol. Swed. Dent. J. 8: 147-154.
23. McAleer, W. J., Markus, H. Z., McLean, A. A., Buynak, E. B. and Hilleman, M. R. 1980. Stability on storage at various temperatures of live measles, mumps, and rubella virus vaccines in new stabilizer. J. Biol. Stand. 8: 281-287.
24. Hilleman, M. R., Buynak, E. B., Weibel, R. E., Stokes, J. Jr., Whitman, J. E. Jr. and Leagus, M. B. 1968. Development and evaluation of the Moraten measles virus vaccine. J. Am. Med. Assoc. 206: 587-590.
25. Buynak, E. B. and Hilleman, M. R. 1966. Live attenuated mumps virus vaccine. 1. Vaccine development. Proc. Soc. Exp. Biol. Med. 123: 768-775.
26. Buynak, E. B., Larson, V. M., McAleer, W. J., Mascoli, C. C. and Hilleman, M. R. 1969. Preparation and testing of duck embryo cell culture rubella vaccine. Am J. Dis. Child. 118: 347-354.
27. Buynak, E. B., Weibel, R. E., Whitman, J. E. Jr. and Hilleman, M. R. 1969. Combined live measles, mumps, and rubella virus vaccine. J. Am. Med. Assoc. 207: 2259-2262.